Tag:

Charles River

Latest Headlines

Latest Headlines

Charles River deepens its ties to Huntington's R&D with new deal

Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.

Timely deals boost Charles River's balance sheet

A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.

Charles River debuts new testing tech for quality control

Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.

With help from Charles River, AstraZeneca expands its respiratory pipeline

AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.

Charles River's checkbook fuels a leap in revenue

Charles River Laboratories is dialing up its expectations for the year after some M&A padded its second-quarter results, riding a 16.5% boost in sales.

NCI backs out of a $34M deal with Charles River, putting jobs in jeopardy

The National Cancer Institute is terminating a $34 million mouse-model contract with Charles River Laboratories, possibly imperiling jobs at one of the CRO's Maryland outposts.

Charles River ticks up revenue with M&A on tap

Charles River Laboratories posted a slight increase in sales last quarter, crediting a rise in preclinical demand as it counts on some new acquisitions to brighten 2014.

Charles River wraps up $179M deal for Galapagos' CRO biz

Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.

Galapagos ships out its CRO biz for $179M to focus on R&D

Belgian biotech Galapagos is getting out of the CRO business, selling off its two contract units to preclinical giant Charles River Laboratories for $179 million and planning to put the proceeds into its pipeline.

Charles River snaps up Galapagos' CRO biz for $179M

Charles River Laboratories is looking to pad its preclinical prowess, inking a $179 million deal with drugmaker Galapagos for two CRO subsidiaries and a chance to expand its in vitro biology expertise.